Cellcept (mycophenolate mofetil) should be the first-line treatment for most patients with ILD
For patients with systemic autoimmune rheumatic disease-associated ILD (SARD-ILD), mycophenolate is conditionally recommended as a first-line treatment option, whereas Jascayd (nerandomilast) is not yet included in established treatment guidelines. 1
Evidence-Based Treatment Algorithm
First-Line Treatment Selection
Cellcept (mycophenolate mofetil) is the established choice based on the 2023 ACR/CHEST guidelines, which conditionally recommend mycophenolate, azathioprine, rituximab, and cyclophosphamide as first-line ILD treatment options for SARD-ILD 1. Mycophenolate has demonstrated:
- FVC stabilization or improvement in multiple connective tissue disease-associated ILDs
- Lower toxicity profile compared to cyclophosphamide
- Extensive clinical experience across multiple ILD subtypes 1, 2
Jascayd (nerandomilast) lacks guideline support for first-line use in autoimmune ILD. While FDA-approved for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), its approval specifically excluded patients on mycophenolate, cyclophosphamide, tocilizumab, or rituximab within 8 weeks prior to trials 3. The drug was studied primarily in:
- IPF patients (reduced FVC decline by 64 mL vs placebo at 52 weeks)
- PPF patients (28% had autoimmune ILDs, but these were mixed with other etiologies) 3
Critical Exclusion Criteria from Jascayd Trials
The FIBRONEER-ILD trial specifically excluded patients on prednisone >15 mg/day, mycophenolate, cyclophosphamide, tocilizumab within 8 weeks, or rituximab within 6 months 3. This means Jascayd has not been studied in combination with standard immunosuppressive therapy that most autoimmune ILD patients require.
Disease-Specific Considerations
For Autoimmune/Connective Tissue Disease-ILD:
- Start with Cellcept 2g daily as first-line immunosuppression 1, 4
- Consider adding rituximab if inadequate response (combination showed 3.60% better FVC preservation vs mycophenolate alone) 4
- Reserve Jascayd for progressive fibrosing disease despite immunosuppression, similar to nintedanib's role 1
For Progressive Pulmonary Fibrosis (PPF):
- If patient has underlying autoimmune disease: Cellcept remains first-line
- If patient has failed immunosuppression or has non-autoimmune PPF: Consider Jascayd as it showed 64-91 mL reduction in FVC decline 3
Safety Profile Comparison
Cellcept has well-established monitoring requirements:
- CBC, liver function tests at baseline, monthly initially
- Known risks: infections, GI symptoms, teratogenicity 5
Jascayd carries additional concerns:
- Suicidal ideation/behavior warnings (excluded patients with history of suicidal behavior from trials) 3
- Less established safety profile in autoimmune disease populations
- No data on combination with standard immunosuppressants 3
Common Pitfalls to Avoid
- Do not use Jascayd as first-line in autoimmune ILD - it bypasses necessary immunosuppression and lacks guideline support
- Do not combine Jascayd with pirfenidone - efficacy was not observed in this combination 3
- Do not delay immunosuppression in autoimmune ILD by starting with antifibrotics alone - the inflammatory component requires immunomodulation 1
When to Consider Jascayd
Jascayd may be appropriate as second-line or add-on therapy in these specific scenarios:
- Progressive fibrosing ILD despite adequate immunosuppression with mycophenolate
- Patient cannot tolerate or has contraindications to standard immunosuppressants
- Non-autoimmune progressive pulmonary fibrosis
- As alternative to nintedanib (both are antifibrotics, but Jascayd may have additional immunomodulatory properties) 6
The guideline explicitly recommends against upfront combination of antifibrotics (like nintedanib or pirfenidone) with mycophenolate over mycophenolate alone 1, and this principle would extend to Jascayd until proven otherwise.